In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

J Clin Ultrasound. 2015 Sep;43(7):451-7. doi: 10.1002/jcu.22214. Epub 2014 Jul 15.

Abstract

Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.

Keywords: congenital cystic adenomatoid malformation; hydrops fetalis; obstetrics Adzick's classification; sonography.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Betamethasone / therapeutic use*
  • Cystic Adenomatoid Malformation of Lung, Congenital / diagnostic imaging
  • Cystic Adenomatoid Malformation of Lung, Congenital / drug therapy*
  • Female
  • Fetal Diseases / diagnostic imaging
  • Fetal Diseases / drug therapy*
  • Glucocorticoids / therapeutic use*
  • Humans
  • Pregnancy
  • Treatment Outcome
  • Ultrasonography, Prenatal

Substances

  • Glucocorticoids
  • Betamethasone